Archive for month: August, 2024

As per the schedule, the NEET-UG 2024 counselling will begin on August 18, 2024, and end on October 26, 2024, at 5 PM. With this, the registration process will begin from August 18, 2024, and will continue till August 24, 2024. Below is the detailed schedule-

SCHEDULE

STEPS TO REGISTER FOR CHATTISGARH NEET UG 2024 COUNSELLING

STEP 1- Visit the official website of Chhattisgarh counselling.

STEP 2- Register using a valid email ID and mobile number.

STEP 3- Fill the required details in the application form carefully.

STEP 4- Set a password and choose a security question.

STEP 5- Pay the registration fee as directed by the DME Raipur.

STEP 6- Login ID and password will be sent to the registered email ID.

To view the schedule, click the link below

New Delhi: The drug major Zydus Lifscience has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the phase IV clinical trial of the vaccine Measles and Rubella Vaccine (Live) I.P. (Freeze Dried).

This came after the firm presented the Phase IV clinical trial protocol of Measles and Rubella Vaccine (Live) I.P. (Freeze Dried) titled “A prospective, randomized, parallel, single-blind, four-arm, active-controlled, multicentre, Phase IV clinical trial to evaluate the immunogenicity and safety of Measles and Rubella Vaccine (Live) I.P. compared to Measles and Rubella vaccine (Live) I.P. (Freeze Dried) of M/s Serum Institute of India Pvt. Ltd. and to evaluate lot-to-lot consistency of Measles and Rubella vaccine (Live) I.P. (Freeze Dried) of M/s Zydus Life sciences Ltd. in healthy infants aged 9-12 months. “

Measles and Rubella Vaccine (Live) I.P. (Freeze Dried) is a sterile, white, dull appearance to a very light pinkish-colored cake, cake turns into clear solution of red to purple colour after reconstitution with diluent.

It’s a live-attenuated viral vaccine that consists of the Edmonston Zagreb strain of measles virus and RA27/3 strain of rubella virus propagated on Human Diploid Cells. The vaccine meets the requirements of I.P. and WHO when tested by the methods outlined in I.P. and WHO, TRS 840 (1994).

Measles causes fever, cough, runny nose, and red, watery eyes, commonly followed by a rash that covers the whole body. It can lead to seizures (often associated with fever), ear infections, diarrhea, and pneumonia. Rarely, measles can cause brain damage or death.

Rubella causes fever, sore throat, rash, headache, and eye irritation. It can cause arthritis in up to half of teenage and adult women. If a person gets rubella while they are pregnant, they could have a miscarriage, or the baby could be born with serious birth defects.

The measles and rubella virus vaccine live is an active immunizing agent used to prevent infection by the measles and rubella viruses. It works by causing the body to produce its own protection (antibodies) against the viruses.

At the recent SEC meeting for Vaccine held on July 31, 2024, the expert panel reviewed the Phase IV clinical trial protocol of Measles and Rubella Vaccine (Live) I.P. (Freeze Dried) presented by the drug Zydus Lifscience.

After detailed deliberation, the committee recommended approval to conduct the Phase-IV clinical trial as per the presented protocol.

Also Read: Justify proposed dose and rationality: CDSCO Panel Tells Lupin on FDC Sacubitril plus Valsartan

New Delhi: In response to the proposal presented by the drug maker Windlass Biotech, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has recommended the firm revise the Phase III clinical trial protocol of the fixed-dose combination (FDC) Tamsulosin Hydrochloride IP (MR) 0.4 mg/0.4 mg plus Mirabegron (ER) 25 mg/50 mg tablets.

This came after the firm presented the proposal along with a bioequivalence (BE) study report and Phase III clinical trial study protocol before the committee.

The expert panel stated that the protocol is not scientifically justified and needs to be revised for better justification. Furthermore, the expert panel added that BPH patient inclusion criteria should be revised for their confirmed diagnosis and the firm should change the comparator arm.

Tamsulosin is used to treat men who have symptoms of an enlarged prostate gland, which is also known as benign enlargement of the prostate (benign prostatic hyperplasia or BPH). Benign enlargement of the prostate is a problem that can occur in men as they get older. The prostate gland is located below the bladder.

Mirabegron, a beta-3 adrenoceptor agonist, has been shown to have a high safety and efficacy profile in large random placebo-controlled clinical trials. Mirabegron is used to treat urgency, urge urinary incontinence, and increased urinary frequency found in the overactive bladder.

At the recent SEC meeting for Urology held on 25th July 2024, the expert panel reviewed the proposal along with a BE study report and Phase III CT study protocol of the Tamsulosin Hydrochloride plus Mirabegron tablets presented by drug major Windlass Biotech.

After detailed deliberation, the committee considered a BE study report. As regards the Phase III clinical trial protocol, the committee opined that:

1. The protocol is not scientifically justified and needs to be revised for better justification.

2. BPH patient inclusion criteria should be revised for their confirmed diagnosis.

3. The firm should change the comparator arm.

Accordingly, a revised Phase III clinical trial protocol should be submitted to CDSCO for further review by the committee.

Also Read: Submit clinical study data conducted in adults: CDSCO Panel Tells Sanofi on atopic dermatitis drug

In this regard, JIPMER has released a prospectus giving details of seat distribution, course information, admission procedure, fee structure etc of the MBBS course. Below are the detailed information for the candidates willing to take admission to the MBBS course for the academic year 2024-25 at JIPMER Puducherry and Karaikal campuses.

ADMISSION PROCESS

The counselling for admission to MBBS courses in JIPMER Puducherry and Karaikal campuses will be conducted by the Medical Counselling Committee (MCC), Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India based on the National Testing Agency (NTA) National Eligibility and Entrance Test (NEET) 2024 All-India scores.

Meanwhile, the counselling and admissions at the Puducherry and Karaikal campuses of JIPMER are considered as separate entities and therefore the admission process will be held at the respective campuses.

The admission process for the JIPMER Puducherry will be held at the JIPMER Academic Centre (JAC), JIPMER, Puducherry. Similarly, the admission process for the JIPMER Karaikaal will be held at the new academic building, JIPMER, Karaikal.

The candidates should bring all the certificates in original, One set of self-attested photocopies of all the certificates and Three Passport size recent colour photographs at the time of admission within the stipulated time, failing which, admission will be denied. Below are the lists of certificates to be submitted at the time of admission-

1 Identity proof.

2 Admit Cards of Exam issued by NTA.

3 Result/ Rank letter issued by NTA.

4 Provisional allotment letters generated through online.

5 Proof of Date of Birth (Birth Certificate or X Std. Certificate).

6 10th Standard Certificate.

7 Pass Certificate of the qualifying examination.

8 Statement of marks of the qualifying examination.

9 Character/ Conduct Certificate from the Head of the Institute last studied.

10 Residence Certificates issued by the Revenue Authority, not below the rank of Tahsildar /Aadhaar card.

11 In the case of Other Backward Classes/ Scheduled Caste/ Scheduled Tribe, a Community Certificate, was recently obtained from the competent authority.

12 Economically Weaker Sections (EWSs) candidates should produce the required Income & Asset Certificate.

13 Transfer/ Migration Certificate from the Head of the Institution last studied.

14 In case of Puducherry residents, the Residence Certificate / Employer Certificate.

15 Medical Certificate from the authorised centres.

With this, all candidates should report within the time mentioned in their ‘allotment letter’, failing which, they will forfeit the right to admission. At any time, if the competent authorities find that admission was sought based on false/ incorrect information/ documents and suppression of relevant facts, educational qualification or quota, the admission offered or the admission already completed will be cancelled, irrespective of the stage of study of that course. Further, legal proceedings will also be initiated against such candidates for such action/(s). Hence, candidates are warned against indulging in such action(s), in their own interest.

Meanwhile, all the parents are also requested to make note of the above provision and take due care and diligence, in all matters concerning admission to the courses.

ADMISSIONS TO THE MBBS COURSE WILL BE REJECTED IN THE FOLLOWING SITUATIONS

1 Candidates who fail to fulfil the prescribed age limit criteria.

2 Candidates who fail to obtain the minimum stipulated marks in the qualifying examination.

3 Candidates who have applied under the Non-Creamy Layer OBC Category and whose subcaste is NOT listed in the current Central OBC List and whose certificate has NOT been submitted in the prescribed format from the Competent Authority.

4 The candidates who have applied under SC/ST Category WITHOUT valid Certificate as in the prescribed format from the Competent Authority.

5 The Candidates who have applied under Puducherry-domicile status with no valid proof.

DURATION

The total duration of the MBBS course at JIPMER Puducherry and Karaikal is 4 years and 6 months followed by one year of Compulsory Rotatory Internship for the award of the Degree. The maximum duration of the course excluding the internship period is 9 years. The maximum permissible duration for each phase will be 4 years and a maximum 4 number of attempts per subject, whichever is earlier. If a candidate fails to complete the course within 9 years, his/her name will be removed from the register of the course.

Each student is required to attend 75% or more of all the scheduled theory and practical classes separately and secure at least 30% internal assessment marks in theory and practical tests separately to be eligible to appear in the Professional Examinations held at the end of each phase. There is no condonation of attendance.

Of the total marks in each subject, the internal assessment will contribute 40% and the final examination will contribute the remaining 60%. This will apply to both the theory and practical/clinical papers separately. The final aggregate marks should be 50% and above in theory and practical papers separately to pass in a subject. However, passing the previous Phase is compulsory before proceeding to the next phase of training.

FEE STRUCTURE

The fees should be paid by the candidates through the SBI Collect payment portal for JIPMER. After visiting the portal for JIPMER, Choose the Academic Fee – PHD MSC MPH MBBS BSC BASLP option in the dropdown menu. Meanwhile, it is to be noted that, fees once paid will not be refunded under any circumstances. A hard copy of the fee payment receipt should be submitted on the day of reporting.

As per the fee structure, the total fee for the MBBS course in both JIPMER Puducherry and Karaikal is Rs 14,920/-.

DISTRIBUTION OF SEATS

The MCC will apply the reservation roster on the seat matrix provided above and publish the reservation category-wise distribution of seats on the MCC official website.

Meanwhile, 5% of the seats are reserved horizontally for the Persons with Benchmark Disability (PwBD) candidates as per the Rights of Persons with Disabilities Act, 2016. If no eligible candidates are available for a seat allotted for PwBD under a category, the seat will be filled by candidates from the same category.

As per the seat matrix, JIPMER Puducherry has a total of 182 vacant seats and JIPMER Karaikal has a total of 61 vacant seats. MBBS Seats in JIPMER Puducherry and Karaikal campuses for the Academic year 2024-25 are as follows-

SEAT MATRIX FOR JIPMER PUDUCHERRY

SEAT MATRIX FOR JIPMER KARAIKAAL

To view the prospectus, click the link below